JP2022528780A5 - - Google Patents

Info

Publication number
JP2022528780A5
JP2022528780A5 JP2021560707A JP2021560707A JP2022528780A5 JP 2022528780 A5 JP2022528780 A5 JP 2022528780A5 JP 2021560707 A JP2021560707 A JP 2021560707A JP 2021560707 A JP2021560707 A JP 2021560707A JP 2022528780 A5 JP2022528780 A5 JP 2022528780A5
Authority
JP
Japan
Prior art keywords
cancer
compound
compound according
inhibitors
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021560707A
Other languages
English (en)
Japanese (ja)
Other versions
JP7568641B2 (ja
JP2022528780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027453 external-priority patent/WO2020210481A1/en
Publication of JP2022528780A publication Critical patent/JP2022528780A/ja
Publication of JP2022528780A5 publication Critical patent/JP2022528780A5/ja
Application granted granted Critical
Publication of JP7568641B2 publication Critical patent/JP7568641B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560707A 2019-04-12 2020-04-09 治療的使用のためのキナーゼ阻害剤としての複素環式化合物 Active JP7568641B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833364P 2019-04-12 2019-04-12
US62/833,364 2019-04-12
PCT/US2020/027453 WO2020210481A1 (en) 2019-04-12 2020-04-09 Heterocyclic compounds as kinase inhibitors for therapeutic uses

Publications (3)

Publication Number Publication Date
JP2022528780A JP2022528780A (ja) 2022-06-15
JP2022528780A5 true JP2022528780A5 (cg-RX-API-DMAC7.html) 2023-04-17
JP7568641B2 JP7568641B2 (ja) 2024-10-16

Family

ID=72751520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560707A Active JP7568641B2 (ja) 2019-04-12 2020-04-09 治療的使用のためのキナーゼ阻害剤としての複素環式化合物

Country Status (9)

Country Link
US (1) US12668584B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952865A4 (cg-RX-API-DMAC7.html)
JP (1) JP7568641B2 (cg-RX-API-DMAC7.html)
KR (1) KR102913995B1 (cg-RX-API-DMAC7.html)
CN (1) CN114025755B (cg-RX-API-DMAC7.html)
AU (1) AU2020271855B2 (cg-RX-API-DMAC7.html)
CA (1) CA3132855A1 (cg-RX-API-DMAC7.html)
TW (1) TWI757722B (cg-RX-API-DMAC7.html)
WO (1) WO2020210481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CN114031561B (zh) * 2021-12-10 2022-12-02 江西科技师范大学 含4-苯氧基喹唑啉类化合物及其应用
KR102910577B1 (ko) * 2022-02-17 2026-01-08 내셔날 헬스 리서치 인스티튜트 융합 다환식 화합물의 제조 방법
CN116763787A (zh) * 2022-03-08 2023-09-19 安徽中科拓苒药物科学研究有限公司 喹啉类化合物的新用途
TW202448857A (zh) * 2023-05-12 2024-12-16 大陸商正大天晴藥業集團股份有限公司 含有芳香二並環的化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298311B1 (en) * 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
HU230863B1 (hu) * 1999-01-13 2018-10-29 Bayer Healthcare Llc Omega-karboxi-arilcsoporttal helyettesített difenil-karbamidok, mint raf-kináz inhibitorok
IL144461A0 (en) 1999-01-22 2002-05-23 Kirin Brewery Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
JP4383870B2 (ja) 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
GB0509224D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
KR101106050B1 (ko) 2009-03-25 2012-01-18 한국과학기술연구원 아미노퀴놀린 화합물, 이의 제조 방법 및 이를 함유하는 의약 조성물
CN101671301B (zh) * 2009-05-05 2014-02-26 江苏省药物研究所有限公司 杂环取代的二苯脲类衍生物及其用途
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
BR112015022263B1 (pt) 2013-03-15 2023-01-03 Deciphera Pharmaceuticals Llc N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica
CN104177346A (zh) 2013-05-21 2014-12-03 苏州科捷生物医药有限公司 喹唑啉类化合物及其用途
SG10201408115SA (en) 2014-12-05 2016-07-28 Chakra Biotech Pte Ltd Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
WO2016161952A1 (zh) 2015-04-07 2016-10-13 广东众生药业股份有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HK1255102A1 (zh) * 2015-09-21 2019-08-02 Plexxikon Inc. 杂环化合物及其应用
US10160747B2 (en) * 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG11201903091VA (en) 2016-10-10 2019-05-30 Dev Ct Biotechnology Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
WO2018081276A1 (en) 2016-10-25 2018-05-03 Tesaro, Inc. Compounds

Similar Documents

Publication Publication Date Title
TWI844568B (zh) 抑制shp2活性化合物之製造方法、及由酸加成產生之產物
JP2019512505A5 (cg-RX-API-DMAC7.html)
KR102534028B1 (ko) 트리아졸로피리미딘 화합물 및 그의 용도
ES2923875T3 (es) Moduladores de la vía integrada del estrés
US12139494B2 (en) Morphic forms of G1T38 and methods of manufacture thereof
TWI757722B (zh) 以雜環化合物作為激酶抑制劑的治療用途
ES2439776T3 (es) Triazolopiridinas sustituidas
US12534472B2 (en) Morphic forms of trilaciclib and methods of manufacture thereof
JP2018537533A5 (cg-RX-API-DMAC7.html)
JP2014503567A5 (cg-RX-API-DMAC7.html)
JP7611154B2 (ja) ピリド-ピリミジニル化合物及び使用の方法
JP2022517189A (ja) 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物
KR20140003436A (ko) 과증식성 장애 및 혈관형성과 관련된 질환 치료에 유용한 아미노알코올 치환된 2,3-디하이드로이미다조[1,2-c]퀴나졸린 유도체
WO2018005533A1 (en) Antiproliferative pyrimidine-based compounds
JP2010531344A5 (cg-RX-API-DMAC7.html)
IL323777A (en) Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
AU2018350980A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
US12006320B2 (en) Heterocyclic derivatives as PI3K inhibitors
WO2021257587A1 (en) Morphic forms of trilaciclib and methods of manufacture thereof
ES2976576T3 (es) Formas cristalinas de un inhibidor de la fosfoinositida 3-quinasa (pi3k)
CA2955878A1 (en) Amino-substituted isoxazoles
WO2023141262A1 (en) Bax activators and use thereof
TW202304906A (zh) 高活性hpk1激酶抑制劑
KR102549484B1 (ko) 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
CN121399105A (zh) 杂芳族dhodh抑制剂